High B7-H3 expression has been associated with worse clinical outcomes for some cancers, including non–small cell lung cancer, breast cancer, colorectal cancer, prostate cancer, and osteosarcoma (8, 9, 12, 13). Here, CD276 is linked to prostate cancer.